Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Unusual zinc-binding mode of HDAC6-selective hydroxamate inhibitors
N.J. Porter, Adaickapillai Mahendran, Ronald Breslow, et al.
Proceedings of the National Academy of Sciences (2017) Vol. 114, Iss. 51, pp. 13459-13464
Open Access | Times Cited: 150

Showing 1-25 of 150 citing articles:

HDAC6 as privileged target in drug discovery: A perspective
Sravani Pulya, Sk. Abdul Amin, Nilanjan Adhikari, et al.
Pharmacological Research (2020) Vol. 163, pp. 105274-105274
Closed Access | Times Cited: 179
A Review of Progress in Histone Deacetylase 6 Inhibitors Research: Structural Specificity and Functional Diversity
Xin-Hui Zhang, Qin-Ma, Hui-Pan Wu, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 3, pp. 1362-1391
Closed Access | Times Cited: 106
Histone deacetylase (HDAC) inhibitors in cancer: a patent review (2017-present)
Chunlong Zhao, Hang Dong, Qifu Xu, et al.
Expert Opinion on Therapeutic Patents (2020) Vol. 30, Iss. 4, pp. 263-274
Closed Access | Times Cited: 111
Characterization of Histone Deacetylase 8 (HDAC8) Selective Inhibition Reveals Specific Active Site Structural and Functional Determinants
Martin Marek, T.B. Shaik, Tino Heimburg, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 10000-10016
Open Access | Times Cited: 103
Structure, mechanism, and inhibition of the zinc-dependent histone deacetylases
N.J. Porter, D.W. Christianson
Current Opinion in Structural Biology (2019) Vol. 59, pp. 9-18
Open Access | Times Cited: 101
Histone Deacetylase 6-Selective Inhibitors and the Influence of Capping Groups on Hydroxamate-Zinc Denticity
N.J. Porter, J.D. Osko, Daniela Diedrich, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 17, pp. 8054-8060
Open Access | Times Cited: 90
Synthesis and Biological Investigation of Phenothiazine-Based Benzhydroxamic Acids as Selective Histone Deacetylase 6 Inhibitors
Katharina Vögerl, Nghia Ong, Johanna Senger, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 3, pp. 1138-1166
Open Access | Times Cited: 88
How Does Chirality Determine the Selective Inhibition of Histone Deacetylase 6? A Lesson from Trichostatin A Enantiomers Based on Molecular Dynamics
Yang Zhang, Jun Ying, Jia Jun Hong, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 5, pp. 2467-2480
Closed Access | Times Cited: 88
Strategies To Design Selective Histone Deacetylase Inhibitors
Jelena Melesina, Conrad V. Simoben, Lucas Praetorius, et al.
ChemMedChem (2021) Vol. 16, Iss. 9, pp. 1336-1359
Closed Access | Times Cited: 84
Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated
Magalie Géraldy, Michael Morgen, Peter Sehr, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 9, pp. 4426-4443
Open Access | Times Cited: 81
Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry Applications
Andrea Citarella, Davide Moi, Luca Pinzi, et al.
ACS Omega (2021) Vol. 6, Iss. 34, pp. 21843-21849
Open Access | Times Cited: 68
The Zinc-Binding Group Effect: Lessons from Non-Hydroxamic Acid Vorinostat Analogs
Silke Geurs, Dorien Clarisse, Karolien De Bosscher, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 12, pp. 7698-7729
Open Access | Times Cited: 24
Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases
D.W. Christianson
Accounts of Chemical Research (2024) Vol. 57, Iss. 8, pp. 1135-1148
Closed Access | Times Cited: 11
Discovery of the First-in-Class Dual Histone Deacetylase–Proteasome Inhibitor
Sanil Bhatia, Viktoria Krieger, M. Groll, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 22, pp. 10299-10309
Open Access | Times Cited: 75
A patent review of histone deacetylase 6 inhibitors in neurodegenerative diseases (2014-2019)
Sida Shen, Alan P. Kozikowski
Expert Opinion on Therapeutic Patents (2019) Vol. 30, Iss. 2, pp. 121-136
Open Access | Times Cited: 71
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models
Sida Shen, Melissa Hadley, Kseniya Ustinova, et al.
Journal of Medicinal Chemistry (2019) Vol. 62, Iss. 18, pp. 8557-8577
Closed Access | Times Cited: 70
Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors
Andreas Sellmer, Hubert Stangl, Mandy Beyer, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 8, pp. 3454-3477
Closed Access | Times Cited: 67
Structural and in Vivo Characterization of Tubastatin A, a Widely Used Histone Deacetylase 6 Inhibitor
Sida Shen, Michal Svoboda, Guangming Zhang, et al.
ACS Medicinal Chemistry Letters (2020) Vol. 11, Iss. 5, pp. 706-712
Open Access | Times Cited: 67
Brain Penetrable Histone Deacetylase 6 Inhibitor SW-100 Ameliorates Memory and Learning Impairments in a Mouse Model of Fragile X Syndrome
Alan P. Kozikowski, Sida Shen, Marta Pardo, et al.
ACS Chemical Neuroscience (2018) Vol. 10, Iss. 3, pp. 1679-1695
Open Access | Times Cited: 59
Structural Basis of Catalysis and Inhibition of HDAC6 CD1, the Enigmatic Catalytic Domain of Histone Deacetylase 6
J.D. Osko, D.W. Christianson
Biochemistry (2019) Vol. 58, Iss. 49, pp. 4912-4924
Open Access | Times Cited: 59
Histone deacetylases as targets for the treatment of neurodegenerative disorders: Challenges and future opportunities
Daniel A. Rodrigues, Pedro de Sena Murteira Pinheiro, Fernanda S. Sagrillo, et al.
Medicinal Research Reviews (2020) Vol. 40, Iss. 6, pp. 2177-2211
Closed Access | Times Cited: 55
Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model
Feng He, C. James Chou, Matthias Scheiner, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 7, pp. 3794-3812
Open Access | Times Cited: 50
Inhibition of Histone Deacetylase 6 (HDAC6) as a therapeutic strategy for Alzheimer's disease: A review (2010–2020)
Yunheng Li, Shenghu Sang, Weijie Ren, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113874-113874
Closed Access | Times Cited: 44
Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention
Dušan Ružić, Nemanja Djoković, Tatjana Srdić‐Rajić, et al.
Pharmaceutics (2022) Vol. 14, Iss. 1, pp. 209-209
Open Access | Times Cited: 37
Targeting histone deacetylases: Emerging applications beyond cancer
Yasir S. Raouf
Drug Discovery Today (2024) Vol. 29, Iss. 9, pp. 104094-104094
Closed Access | Times Cited: 7
Page 1 - Next Page

Scroll to top